Podcasts about ddw

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/44ySoL3Follow along with the slides: https://bit.ly/3IvwQrjGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/4lKaO2HFollow along with the slides: https://bit.ly/44PPBysGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In significant news this week, the FDA in the US has removed red tape that limits which centres could give CAR-T therapy, in a move to improve access to the therapies. The round-up this time focuses on other developments in cell and gene therapies (CGT) including two high profile acquisitions. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Artificial intelligence (AI) and big data are revolutionizing industries—so why is dairy only now catching up? In this episode, we explore: Why the dairy value chain is embracing AI nowHow DDW is using data to support smarter, more sustainable dairy operationsThe journey from raw farm data to actionable AI insights Don't miss this conversation on the future of dairy tech! This episode is sponsored by Dairy Data Warehouse.  At Dairy Data Warehouse (DDW), we unlock the full potential of data on dairy farms across the globe to enable the industry to harness big data and AI for sustainable and more profitable farming. DDW collects farm data from the herd management software and other sources on farm. We ensure high data quality by cleaning and transforming it into a unified, comparable set for AI driven strategic decision-making, benchmarking and insights. Our solutions support key stakeholders in nutrition, genetics, animal health, cow monitoring, and milking equipment. Let's connect to explore how data can drive your business forward.

This is the latest episode of the free DDW narrated podcast, titled "UK Spotlight: Innovation and discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Where is the drug discovery expertise happening in the UK?”, “From the top: Dr Martin Main, Medicines Discovery Catapult”, and “Meet the Researcher: Molly Stevens, Oxford University and Imperial”. In the first article, I highlight the research taking place and where this is happening in the UK, a long-established hub for drug discovery expertise worldwide.  In the second article, I spoke with Dr Martin Main, Chief Scientific Officer, Medicines Discovery Catapult, in the From the Top series.   In the third article, I spoke with Molly Stevens, John Black Professor at Oxford University and Research Director for Biomedical Materials at Imperial College London, as part of the Meet the Researcher series.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we announce the DDW ‘Creating cures' programme at SLAS2026, the week's news highlights emphasise the importance of advanced technologies to the success of drug discovery, including digital control arms for clinical studies, nanobody-based imaging, and new applications for artificial intelligence (AI). You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Professor Jonathan Kagan, a Harvard immunology professor and director of Basic Research at Boston Children's Hospital. He's also the founder of Corner Therapeutics, a biotech startup launched this year with $54 million in funding to develop revolutionary vaccines designed to tackle a virtually unlimited range of diseases, including cancer, HIV, and Covid. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there have been several significant developments in oncology drug discovery, including new therapy options for some difficult to treat cancers. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week's round-up highlights the vital role of genetics in drug discovery, including new data for an Alzheimer's gene therapy, the discovery of a genetic target for rejuvenation therapies, and a 13-year follow up on haemophilia gene therapy patients. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of drug discovery”, and “The era of precision neuroscience”. In the first article, Lu Rahman looks at neuroscience drug discovery – advances and challenges – and how breakthroughs in this field are helping address areas of unmet need. In the second article, James Peach, Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process, shares insight with me.  In the third article, Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments for neurological and neuropsychiatric diseases.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With conference season in full swing and the speakers announced for DDW's Turning Science into Business Symposium in November, our news round-up shines a light on the importance of these in-person events for sharing and discovering the latest drug discovery breakthroughs. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr Emil Lou, Professor of Hematology and Oncology at the University of Minnesota. They discuss the promising results of a recent clinical trial he led focused on gastrointestinal cancers, the potential impact of continued clinical success on the future of these hard-to-treat cancers, and the key challenges that must be addressed to sustain progress. Dr Lou also explores the evolving role of multiplexed gene editing in tackling immunosuppressive or heterogeneous solid tumours, the complexities of forging academia-industry partnerships to support early-phase innovation, and the scientific breakthroughs he believes will shape the next five years in cancer research. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. News stories of note for this week include a major deal signed between Eli Lilly and Rznomics in the field of RNA-editing therapies, and a potential quality-of-life breakthrough for patients with Parkinson's. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “How biomarkers can help discover new treatments for women's health” and “Could NfL accelerate drug development for neurodegenerative diseases?” In the first article, DDW Editor Reece Armstrong speaks to Dr Steve Gardner, Co-Founder and CEO of PrecisionLife about work the company is doing to improve our understanding of endometriosis. In the second article, Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this week focus on drug discovery for metabolic diseases, with a number of developments in treatments for obesity, liver disease, and diabetes. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Phil L'Huillier, CEO of Scancell. Following the company's recent partnership with the NHS Cancer Vaccine Launch Pad, enabling fast-tracked access for melanoma patients, we discuss how Scancell is addressing the scientific, clinical, and logistical challenges of developing therapeutic cancer vaccines—from overcoming tumour heterogeneity and improving immune response to leveraging national infrastructure like the NHS Cancer Vaccine Launch Pad to enable broader, more inclusive trial access. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this time focus on two major regulatory agencies, in a week that saw the European Commission (EC) launch a new fund designed to tempt US researchers to EU countries, and the US Food and Drugs Administration (FDA) roll out extensive new AI systems. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical research?” and “What spatial biology can tell us about disease and drug discovery”. In the first article, DDW Editor Reece Armstrong speaks to Dr Darrell Green, Lecturer in RNA Biology, Biomedical Research Centre, Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development. In the second article, Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. In the third article, DDW Editor Reece Armstrong speaks to Benedikt Nilges, Head of Technology and Data Analytics at OMAPiX about spatial biology's use in drug discovery and bettering our understanding of disease.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our highlights this week demonstrate a variety of approaches to cancer treatment, including a BTK inhibitor, macrophage checkpoint inhibitor, and antibody-drug conjugates, at various stages of development. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Immunic Inc chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about new developments in celiac disease research during Celiac Disease Awareness Month. He emphasized the seriousness of the autoimmune condition, noting it is often misdiagnosed due to vague symptoms. “Celiac disease is a really important disease with significant consequences for patients,” Muehler said, citing malnutrition, infertility, and even malignancy risks as complications. The emotional and social toll of the condition, he added, is also substantial, with many patients facing isolation due to dietary restrictions. Muehler discussed Immunic's investigational drug IMU-856, which targets the SIRT-6 protein to regenerate intestinal lining and strengthen gut barrier function. Early results from a Phase 1b trial involving 43 patients indicated improvements across multiple measures: bowel histology, disease symptoms, biomarkers, and micronutrient absorption. At the recent DDW conference, Immunic presented data showing IMU-856's efficacy even in patients with severe intestinal damage. Additionally, the drug's absorption was not hindered by pre-existing gut damage, an encouraging sign for future use. Muehler also noted the drug's impact on GLP-1 hormone levels, aligning with emerging gastrointestinal treatment trends. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #CeliacDisease #ImmunicInc #IMU856 #AutoimmuneDisorders #GutHealth #BiotechNews #DDW2025 #CeliacTreatment #Epigenetics #GLP1 #MedicalResearch

The latest episode of the DDW Highlights podcast is now available. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the American Association of Cancer Research (AACR) Annual Meeting taking place from 25-30 April, the DDW news desk has been inundated with the latest advances in cancer drug discovery, so here are a few highlights. Check out our round-up for the event for more updates. You can listen here, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dimitrios Goundis, CEO of Kither Biotech. Kither is a Phase I, soon to be Phase II, Italian biotech focused on respiratory diseases such as cystic fibrosis. This episode explores how emerging biotech strategies are advancing treatments for respiratory diseases like cystic fibrosis, with a focus on targeted drug delivery, clinical trial progression, and the evolving biotech landscape in Europe. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “An overview on the impact of synthetic biology”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Synthetic biology: Impacting drug discovery” and “Synthetic biology: Innovating in drug discovery” In the first article, Mark Kotter, Founder and CEO of bit.bio, talks with Reece Armstrong about different approaches to synthetic biology and its applications in programming stem cells into mature, functional human cells for drug discovery and the creation of next generation. In the second article, Reece Armstrong examines recent activity within the synthetic biology sector and highlights some of the key advancements and innovation.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug to market, having announced positive topline results from a Phase III trial, this week our news highlights focus on clinical studies. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer's treatments”, “The start-up disrupting the field of women's reproductive health” and “India: Why is the country ramping up drug discovery research?” Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer's disease. The focus of the trial is to test Cognition Therapeutics' experimental drug, CT1812 for patients with dementia with Lewy Bodies and dry age-related macular degeneration. In the first article, Reece Armstrong speaks to Lisa Ricciardi, CEO of Cognition Therapeutics, to learn about what the company hopes to achieve with CT1812. In the second article, DDW's Diana Spencer speaks to Alok Javali, CSO of dawn-bio, a new addition to BioInnovation Institute's (BII) Venture Lab acceleration programme, about the lack of innovation in women's reproductive health and the company's plans to fill the vacuum. In the third article, I take a deeper look into why India is ramping up drug discovery research, and explores the country's innovation hubs of interest.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week of financial uncertainty for the industry, our round-up focuses on the power of partnership to accelerate drug discovery, from the prevention of respiratory infections, to mapping gene activity in inflammatory bowel disease. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA” and “The microbiome in precision medicine”. In the first article, Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. In the second article, Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio, provide an industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development.

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Sitting down with… Neil Dhawan”, “Meet the researcher: Giusy Di Conza, iOnctura” and “From the Top: Adele Hannigan, Antibody Analytics”. In the first article, Reece Armstrong speaks to Neil Dhawan, the Co-founder and CEO of Totus Medicines about the company's approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). In the second article, Megan Thomas looked at a day in the life of Giusy Di Conza, Head of Research at iOnctura. In the third article, Megan Thomas shines a spotlight on Adele Hannigan, CBO for Antibody Analytics, which has since been rebranded as RoukenBio.

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases will benefit from therapeutic antibody development?” In the first article, Katie Abouzahr is the Vice President, Autoantibody Portfolio and Maternal Fetal Disease Area Leader at the Janssen Pharmaceutical Companies of Johnson & Johnson. She speaks with Megan Thomas about the future for Janssen's investigational medicine nipocalimab and antibody therapeutics at large. In the second article, DDW's Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies.

We talk with Sam Williams of Ultimate Derby and the one and only Chris Deflorian of DDW about the first show struggles at Madison, for a little more in depth take on the show. Hope you enjoy the listen

The latest episode of the DDW Highlights podcast is now available to listen. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Weight loss drugs have been making the news this week. As we come to the end of Women's History Month, two of the covered studies focus on women's health, specifically the role of weight loss drugs in treating endometriosis and why women have worse side effects from these therapeutics.  You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “CRISPR breakthroughs: New solutions for common diseases” and “Re-assessing the risks of drug-induced arrhythmias during drug discovery”.  In the first article, Rolf Turk, Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. In the second article, Dr Mark Treherne, Dr Jack Scannell and Dr Richard Saumarez answer the question: Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods?

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week the DDW news round-up takes a look at developments in cancer research, including AZ's acquisition of EsoBiotec, positive trial results for an allogeneic T-cell therapy, and a new drug target for glioblastoma. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Critical tools that support drug discovery and development”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “You think you need an ELN… but are you asking the right questions?” and “Big data: Charting a new path to drug discovery and development”. In the first article, Matt Clifford, Director of Research and Innovation Strategy at IDBS, discusses the questions that need to be asked if you're considering an ELN.  In the second article, Tim Lowery, President of JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials of all stages have dominated the DDW news section this week. All the stories represent a significant step forward for drug discovery, either due to the innovative nature of the therapies being studied, or the unique methods employed in the trial. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “The revolutionary impact of understanding genomics”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Open science, genomics, and the quiet revolution in our approach to pharma” and “Junk DNA: How the dark genome is changing RNA therapies”. In the first article, Evan Floden, CEO of Seqera Labs, examines how data sharing platforms are impacting cancer and genomics research. In the second article, Samir Ounzain, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are coming through and sparking new life into various areas of drug discovery. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Where are the global epicentres of drug discovery innovation?”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Where are the hottest drug discovery hubs in the US? and Global start-ups: where is the innovation? In the first article, I take a snapshot of the US biotech market and some of the ongoing research coming out of the US. In the second, DDW editors take a look at some key global activity taking place around the world for drug discovery and life sciences start-ups.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It's been a mixed bag of news for gene therapies this week, ranging from huge successes in treating sight impairment, cystic fibrosis and hearing loss, to the quick sale of a previously successful gene therapy developer. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following the news of cuts to medical research funding from the National Institutes of Health (NIH), this week we focus on some positive drug discovery news from North America, including FDA priority review for a number of innovative therapeutics and a new US centre for rare disease research. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Love is in their air this Valentine's Day as this week's news round-up celebrates the importance of collaboration in life sciences, whether that's in the sharing of data, technology, or expertise. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “The continued evidence of AI's drug discovery value”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “How generative AI could improve drug discovery” and “Can artificial intelligence help craft new medicines?” Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. In the first article, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within drug discovery and the company's work in the antibodies sector. In the second article, Professor Sonika Bhatnagar explores how artificial intelligence is enabling drug discovery at rates never seen before.

The latest episode of the DDW Highlights podcast is now available. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following World Cancer Day on 4 February, the news round-up this week focuses on new approaches to the treatment of cancer, including radiopharmaceuticals, programmable cell depletion and preventative vaccines. You can listen here, or find The Drug Discovery World Podcast on Spotify or Google Play.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, we have seen a number of breakthroughs in the treatment of solid tumours, both in the early preclinical and later clinical stages of research.  You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early clinical and preclinical development of immunotherapies, including an islet cell therapy for diabetes, an antibody-drug conjugate and a CAR-T therapy for multiple myeloma, and a peptide-drug conjugate and a vaccine for head and neck cancers. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up at the end of last year focused on drug discovery investment, so it is positive to see that this has also started strong in 2025, with a number of new acquisitions, research partnership agreements and financings to kick off the new year. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “The Achilles' heel of cancer”, and “Immunotherapy is here to stay”. At the time of writing in the first article, AstraZeneca UK had appointed David Brocklehurst as Head of Oncology in the UK. I spoke with him about how AstraZeneca is innovating to displace chemotherapy and research areas of significance. In the second article, Genoscience Pharma's Philippe Halfon and Eric Raymond share their expertise on targeting the recycling of unsustainable production of palmitoylated cancer-associated proteins.  In the third article, I spoke with Frédéric Triebel, the French immunologist/oncologist who is best known for his 1990 discovery of the LAG-3 immune control mechanism. Triebel shares insights from his career, expands on his experience with the company he founded, Immutep, and comments on the future of immuno-oncology.

This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development?, Sitting Down With Dr Harren Jhoti, Astex Pharmaceuticals, and The Nobel Prize winning power of click chemistry. In the first article, Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne, and Dr Jenny Barnett explore the effects of long Covid symptoms and what the opportunities are for drug developers working to treat post-Covid cognitive impairment. In the second article, Dr Harren Jhoti speaks to Diana Spencer after receiving his OBE, about his career, the UK life sciences sector, fragment-based drug discovery and what the future holds for the industry. In the third article, José Mejía Oneto, PhD, Founder and CEO at Shasqi, discusses the potential of chemistry to engineer biology to improve the effectiveness of human therapeutics and revolutionise the treatment of disease.

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we approach the end of 2024, it's great to see that investment in drug discovery is still going strong, with an impressive $300 million raised by AI-focused company SandboxAQ and another significant financing by Ottimo Pharma. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In this episode, Dr. Gandolfo addresses a compelling question from a listener who is curious about the use of GLP-1 drugs, such as Ozempic and Mounjaro, in patients with inflammatory bowel diseases like Crohn's and ulcerative colitis. Dr. Gandolfo provides a comprehensive overview of GLP-1 drugs, explaining how they function as agonists to stimulate insulin secretion and promote weight loss by altering gut motility and suppressing appetite. Delving into the potential implications for patients with inflammatory bowel disease, Dr. Gandolfo explores recent studies suggesting that GLP-1 drugs might be well-tolerated and could even offer benefits in reducing bowel frequency for patients who have undergone colectomy. While these findings are promising, he emphasizes the need for further human studies to confirm these effects. Dr. Gandolfo also addresses common side effects associated with GLP-1 drugs, such as nausea, and reassures listeners about the overall safety of these medications. He highlights the importance of discussing individual risks and benefits with a healthcare provider before starting any new treatment. Referenced in this episode: DDW abstract on safety of GLP-1 drugs with IBD Study of GLP-1 drugs and risk of IBD flare GLP-1 drugs and possible mechanism of benefit in IBD patients Pilot study using GLP-1 agonist to reduce diarrhea in colectomy patients Review of mechanism of action of GLP-1 Be sure to subscribe to The Real GI Doc Show for more insights, and reach out with your questions on social media @realgidoc or leave an audio question for Dr. Gandolfo here. Find The Real GI Doc Show on social media, join the newsletter, read Dr. Gandolfo's bio, or ask a question using this link.